Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Curis ( (CRIS) ) is now available.
On February 21, 2025, Curis, Inc. was notified by Nasdaq that it was not in compliance with the market value listing standard, as its securities’ market value had been below $35 million for 30 consecutive trading days. Despite a 180-day compliance period ending on August 20, 2025, Curis failed to meet the requirement and was informed on August 21, 2025, that its securities would be delisted unless it appealed the decision. Curis intends to request a hearing to appeal, which will temporarily halt the delisting process, but there is no guarantee of regaining compliance.
The most recent analyst rating on (CRIS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Curis stock, see the CRIS Stock Forecast page.
Spark’s Take on CRIS Stock
According to Spark, TipRanks’ AI Analyst, CRIS is a Neutral.
Curis’ overall stock score is primarily impacted by its weak financial performance and unattractive valuation, reflecting ongoing losses and financial instability. While there are positive developments in clinical trials, the limited cash runway and regulatory uncertainties pose significant risks. The technical analysis further indicates bearish momentum, contributing to the low score.
To see Spark’s full report on CRIS stock, click here.
More about Curis
Curis, Inc. operates in the biotechnology industry, focusing on the development and commercialization of innovative therapeutics for the treatment of cancer.
Average Trading Volume: 108,104
Technical Sentiment Signal: Sell
Current Market Cap: $20M
For detailed information about CRIS stock, go to TipRanks’ Stock Analysis page.